EP 3618802 A1 20200311 - USE OF A NEPHELIUM LAPPACEUM EXTRACT FOR INCREASING THE FIRMNESS OF THE SKIN AND/OR OF THE MUCOUS MEMBRANES
Title (en)
USE OF A NEPHELIUM LAPPACEUM EXTRACT FOR INCREASING THE FIRMNESS OF THE SKIN AND/OR OF THE MUCOUS MEMBRANES
Title (de)
VERWENDUNG EINES NEPHELIUM-LAPPACEUM-EXTRAKTES ZUR ERHÖHUNG DER FESTIGKEIT DER HAUT UND/ODER DER SCHLEIMHÄUTE
Title (fr)
UTILISATION D'UN EXTRAIT DE NEPHELIUM LAPPACEUM POUR AUGMENTER LA FERMETÉ DE LA PEAU ET/OU DES MUQUEUSES
Publication
Application
Priority
- FR 1753987 A 20170505
- FR 2018051095 W 20180503
Abstract (en)
[origin: WO2018203000A1] The invention relates to the use of various extracts of the plant Nephelium lappaceum for increasing the firmness and/or the elasticity of the skin and/or the mucous membranes, by increasing type I and/or V collagen and/or LOX-L, fibulin-5, Emiline-1 and/or fibrillin-1 gene and/or protein expression, and/or by decreasing CYR61 expression, in the skin and the mucous membranes. Another subject of the invention relates to the use of said extracts in a cosmetic composition comprising at least one cosmetically acceptable excipient. Another subject relates further to a cosmetic care process comprising the application of the extract according to the invention or of a cosmetic composition comprising same, for increasing the firmness and/or the elasticity of the skin and/or of the mucus membranes, by increasing type I and/or V collagen, fibrillin-1 and/or LOX-L, fibulin-5, Emiline-1 and/or fibrillin-1 gene and/or protein expression, and/or by decreasing CYR61 expression, in the skin and the mucous membranes. A final subject of the invention relates to an N. lappaceum extract for use thereof alone or in a dermatological or pharmaceutical composition in the prevention and/or treatment of pathological conditions involving a loss of collagen protein and/or gene expression and/or a pathological loss of firmness of the skin and/or of the mucous membranes, such as rosacea and telangiectasia.
IPC 8 full level
A61K 8/9789 (2017.01); A61K 36/77 (2006.01); A61Q 19/00 (2006.01); A61Q 19/06 (2006.01); A61Q 19/08 (2006.01)
CPC (source: EP KR US)
A61K 8/9789 (2017.07 - EP KR US); A61K 36/77 (2013.01 - EP KR US); A61P 17/00 (2017.12 - EP KR US); A61Q 19/00 (2013.01 - KR); A61Q 19/004 (2013.01 - EP); A61Q 19/06 (2013.01 - EP US); A61Q 19/08 (2013.01 - EP KR US); A61K 9/0014 (2013.01 - US); A61K 9/0053 (2013.01 - US); A61K 2236/33 (2013.01 - EP US); A61K 2800/78 (2013.01 - EP US)
Citation (search report)
See references of WO 2018203000A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2018203000 A1 20181108; BR 112019022610 A2 20200519; BR 112019022610 B1 20230131; CN 110603031 A 20191220; EP 3618802 A1 20200311; FR 3065876 A1 20181109; FR 3065876 B1 20200814; JP 2020518593 A 20200625; JP 2023052050 A 20230411; KR 102588031 B1 20231011; KR 20200002922 A 20200108; US 11517520 B2 20221206; US 2020078291 A1 20200312
DOCDB simple family (application)
FR 2018051095 W 20180503; BR 112019022610 A 20180503; CN 201880029897 A 20180503; EP 18728212 A 20180503; FR 1753987 A 20170505; JP 2019559749 A 20180503; JP 2022206171 A 20221223; KR 20197033804 A 20180503; US 201816610942 A 20180503